Amgen Inc ((AMGN)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Amgen Inc. is conducting a Phase 1b clinical study titled ‘A Phase 1b, Open-label, Multicenter Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Subjects With High-risk Biochemical Recurrence of Nonmetastatic Castration-sensitive Prostate Cancer After Definitive Therapy.’ The study aims to assess the safety and tolerability of xaluritamig monotherapy in adults with high-risk biochemical recurrent nonmetastatic castration-sensitive prostate cancer, a significant area of unmet medical need.
The intervention being tested is Xaluritamig, an experimental drug administered as a short-term intravenous infusion over six cycles, each lasting 28 days. This treatment is designed to manage prostate cancer that has recurred biochemically but remains nonmetastatic and castration-sensitive.
This interventional study follows a single-group assignment model with no masking, focusing primarily on treatment. The study is open-label, meaning both researchers and participants know the treatment being administered.
The study began on September 23, 2024, with the latest update submitted on July 16, 2025. These dates are crucial as they mark the study’s progression and provide a timeline for potential results and further updates.
The ongoing study could impact Amgen’s stock performance positively if results show favorable outcomes, potentially enhancing investor sentiment. In the competitive landscape of prostate cancer treatments, successful trials could position Amgen as a leader in this niche market.
The study is currently recruiting, and further details are available on the ClinicalTrials portal.